Eye on AMD™ — On your side against MACULAR DEGENERATION

Don't Let Growing
Older Change Your
Focus on Life.

HEAR ABOUT THIS TOPIC:

How LUCENTIS Can Help

Wet age-related macular degeneration (AMD) is a chronic condition that can lead to the loss of central vision if not treated. But it doesn't have to. Having wet AMD may no longer mean losing your eyesight. Nor does it have to mean giving up the things that you enjoy.

For the first time, people with wet AMD have hope of better vision with LUCENTIS^® (ranibizumab injection). In key clinical studies, about 95% of patients treated monthly with LUCENTIS found that their vision stayed the same (lost fewer than 15 letters or 3 lines) and up to 40% of those patients found that their vision significantly improved. And, LUCENTIS is the first FDA approved wet AMD treatment that has shown such positive results.

Results You Can Look Forward To

Of those taking LUCENTIS monthly...

Up to 40% of patients had a significant improvement of at least 3 more lines (15 letters) on the eye chart
70% of patients could see at least 1 more letter on the eye chart
95% of patients had their eyesight stay the same (lost fewer than 15 letters or 3 lines)
Up to 40% of patients achieved vision of 20/40 or better

And, did you know that LUCENTIS was specifically developed for use in the eye, and is FDA approved for the treatment of wet AMD?

In 3 clinical studies, patients were given LUCENTIS on 2 different treatment schedules. Patients were given LUCENTIS monthly in 2 studies. In another study, patients were given 4 monthly LUCENTIS injections and then received injections once every 3 months. Treating with LUCENTIS monthly gives you the best chance to improve your vision. Patients that received LUCENTIS monthly for only 4 months saw a gradual loss in their vision (approximately 5 letters or 1 line) over the following 9 months.

Because everyone is different, your retina specialist will regularly monitor your vision and determine the right treatment schedule for you.

Next > Treatments: What to Expect

Who is LUCENTIS for?

LUCENTIS^® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (AMD).

What important safety information should I know about LUCENTIS?

Like any prescription medication, LUCENTIS is not for everyone. You should not use LUCENTIS if you have an infection in or around the eye.

Like other injections given into the eye, serious eye infection (endophthalmitis) and detached retina have occurred with LUCENTIS. Increases in eye pressure have been seen within 1 hour of an injection. Your eye doctor should monitor your eye pressure and eye health during the week after the injection. If your eye becomes red, sensitive to light, painful, or has a change in vision, you should seek immediate care from your eye doctor.

Although uncommon, conditions associated with eye- and non–eye-related blood clots (arterial thromboembolic events) may occur.

Serious side effects related to the injection procedure were rare. These included serious eye infection, detached retina, and cataract. Other uncommon serious side effects included inflammation inside the eye and increased eye pressure.

The most common eye-related side effects were red eye, eye pain, small specks in vision, the feeling that something is in your eye, and increased tears. The most common non-eye-related side effects were high blood pressure, nose and throat infection, and headache.

LUCENTIS is for Prescription use only. Individual results with LUCENTIS may vary. Please see LUCENTIS full Prescribing Information. For more information visit www.LUCENTIS.com.